دورية أكاديمية
أعرض في EDS

Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases.

التفاصيل البيبلوغرافية
العنوان: Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases.
المؤلفون: Wang X; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai 200032, China., Xia S; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai 200032, China., Wang Q; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai 200032, China., Xu W; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai 200032, China., Li W; Key Laboratory of Reproduction Regulation of National Health Commission, (Shanghai Institute of Planned Parenthood Research), Fudan University, Shanghai 200032, China., Lu L; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai 200032, China., Jiang S; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.; Key Laboratory of Reproduction Regulation of National Health Commission, (Shanghai Institute of Planned Parenthood Research), Fudan University, Shanghai 200032, China.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2020 May 28; Vol. 21 (11). Date of Electronic Publication: 2020 May 28.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Betacoronavirus/*drug effects , Coronavirus Infections/*drug therapy , Protease Inhibitors/*therapeutic use , Viral Fusion Protein Inhibitors/*therapeutic use, Animals ; Betacoronavirus/physiology ; Humans ; Protease Inhibitors/adverse effects ; Protease Inhibitors/pharmacology ; SARS-CoV-2 ; Viral Fusion Protein Inhibitors/adverse effects ; Viral Fusion Protein Inhibitors/pharmacology ; Virus Internalization/drug effects
مستخلص: In the past 17 years, three novel coronaviruses have caused severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and the coronavirus disease 2019 (COVID-19). As emerging infectious diseases, they were characterized by their novel pathogens and transmissibility without available clinical drugs or vaccines. This is especially true for the newly identified COVID-19 caused by SARS coronavirus 2 (SARS-CoV-2) for which, to date, no specific antiviral drugs or vaccines have been approved. Similar to SARS and MERS, the lag time in the development of therapeutics is likely to take months to years. These facts call for the development of broad-spectrum anti-coronavirus drugs targeting a conserved target site. This review will systematically describe potential broad-spectrum coronavirus fusion inhibitors, including antibodies, protease inhibitors, and peptide fusion inhibitors, along with a discussion of their advantages and disadvantages.
References: Clin Microbiol Rev. 2015 Apr;28(2):465-522. (PMID: 25810418)
J Exp Med. 1998 Aug 17;188(4):725-34. (PMID: 9705954)
Respir Med Case Rep. 2016 Jun 16;19:21-3. (PMID: 27408783)
Traffic. 2016 Jun;17(6):593-614. (PMID: 26935856)
J Virol. 2009 Aug;83(15):7411-21. (PMID: 19439480)
PLoS Pathog. 2017 Jul 31;13(7):e1006546. (PMID: 28759649)
J Virol. 2008 Apr;82(7):3220-35. (PMID: 18199635)
Nat Med. 2005 Aug;11(8):875-9. (PMID: 16007097)
Emerg Microbes Infect. 2020 Dec;9(1):382-385. (PMID: 32065055)
Nature. 2020 Mar;579(7798):270-273. (PMID: 32015507)
Science. 2020 Mar 13;367(6483):1260-1263. (PMID: 32075877)
J Virol. 2018 Apr 27;92(10):. (PMID: 29514901)
Antiviral Res. 2020 Jun;178:104792. (PMID: 32272173)
Nat Commun. 2014;5:3067. (PMID: 24473083)
Cell Res. 2020 Apr;30(4):343-355. (PMID: 32231345)
Emerg Microbes Infect. 2020 Dec;9(1):275-277. (PMID: 32005086)
Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19970-4. (PMID: 19901337)
Clin Microbiol Rev. 2007 Oct;20(4):660-94. (PMID: 17934078)
Drug Discov Today. 2015 Jan;20(1):122-8. (PMID: 25450771)
Nat Commun. 2020 May 4;11(1):2251. (PMID: 32366817)
Virol Sin. 2020 Jun;35(3):340-343. (PMID: 32236815)
J Virol. 2014 Jul;88(14):7796-805. (PMID: 24789777)
Cell. 2020 Apr 16;181(2):281-292.e6. (PMID: 32155444)
Nat Rev Microbiol. 2009 Mar;7(3):226-36. (PMID: 19198616)
Nature. 2013 Nov 28;503(7477):535-8. (PMID: 24172901)
Antiviral Res. 2013 Oct;100(1):246-54. (PMID: 23994189)
Surgery. 2001 Aug;130(2):175-81. (PMID: 11490346)
Virus Res. 2015 Apr 16;202:120-34. (PMID: 25445340)
J Virol. 2012 Mar;86(5):2856-8. (PMID: 22205743)
Nature. 2013 Mar 14;495(7440):251-4. (PMID: 23486063)
J Virol. 2014 Jun;88(12):7045-53. (PMID: 24719424)
Endocr Metab Immune Disord Drug Targets. 2020;20(6):807-811. (PMID: 32338224)
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6532-6539. (PMID: 27550352)
Cell Mol Immunol. 2020 Jun;17(6):647-649. (PMID: 32313207)
Hypertension. 2004 Dec;44(6):903-6. (PMID: 15492138)
Science. 2001 May 11;292(5519):1102-5. (PMID: 11352064)
Nature. 2005 Jul 7;436(7047):112-6. (PMID: 16001071)
Antiviral Res. 2015 Apr;116:76-84. (PMID: 25666761)
Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12123-8. (PMID: 17620608)
Sci Adv. 2019 Apr 10;5(4):eaav4580. (PMID: 30989115)
J Biol Chem. 2016 Apr 22;291(17):9218-32. (PMID: 26953343)
Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):3048-53. (PMID: 26976607)
Expert Opin Ther Targets. 2017 Feb;21(2):131-143. (PMID: 27936982)
Cell Mol Immunol. 2020 Jun;17(6):613-620. (PMID: 32203189)
J Biol Chem. 2008 Dec 5;283(49):34045-52. (PMID: 18809675)
Lancet. 2004 Mar 20;363(9413):938-47. (PMID: 15043961)
Nature. 1993 Sep 9;365(6442):113. (PMID: 8371754)
Viruses. 2019 Jan 14;11(1):. (PMID: 30646569)
J Virol. 2013 Dec;87(23):12552-61. (PMID: 24027332)
Nat Rev Microbiol. 2016 Aug;14(8):523-34. (PMID: 27344959)
Virol Sin. 2020 Jun;35(3):263-265. (PMID: 32060789)
Nat Microbiol. 2020 Apr;5(4):536-544. (PMID: 32123347)
Nat Commun. 2020 Apr 24;11(1):2070. (PMID: 32332765)
Nat Commun. 2020 Mar 27;11(1):1620. (PMID: 32221306)
Molecules. 2019 Mar 21;24(6):. (PMID: 30901967)
Lancet. 2020 Mar 21;395(10228):949. (PMID: 32087125)
Viruses. 2014 Sep 26;6(9):3683-98. (PMID: 25256397)
Int J Mol Sci. 2018 Feb 06;19(2):. (PMID: 29415501)
J Biol Chem. 2010 Aug 13;285(33):25506-15. (PMID: 20538590)
J Immunol. 2005 Apr 15;174(8):4908-15. (PMID: 15814718)
Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15214-9. (PMID: 25288733)
Cell. 2020 Apr 16;181(2):271-280.e8. (PMID: 32142651)
Antimicrob Agents Chemother. 2020 May 21;64(6):. (PMID: 32312781)
Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2536-41. (PMID: 14983044)
Sci Rep. 2016 Feb 25;6:22008. (PMID: 26911565)
Cell Mol Immunol. 2020 Jul;17(7):765-767. (PMID: 32047258)
J Pathol. 2020 Jul;251(3):228-248. (PMID: 32418199)
Nature. 1992 Jun 4;357(6377):420-2. (PMID: 1350662)
Expert Opin Investig Drugs. 2002 Dec;11(12):1837-43. (PMID: 12457443)
Nature. 2020 Mar;579(7798):265-269. (PMID: 32015508)
معلومات مُعتمدة: 81822045 National Natural Science Foundation of China; 81630090 National Natural Science Foundation of China; 81703571 National Natural Science Foundation of China; 2018ZX10301403 National Megaprojects of China for Major Infectious Diseases
فهرسة مساهمة: Keywords: COVID-19; antibody; entry inhibitor; fusion inhibitor; peptide; protease inhibitor
المشرفين على المادة: 0 (Protease Inhibitors)
0 (Viral Fusion Protein Inhibitors)
تواريخ الأحداث: Date Created: 20200603 Date Completed: 20200608 Latest Revision: 20240730
رمز التحديث: 20240730
مُعرف محوري في PubMed: PMC7311999
DOI: 10.3390/ijms21113843
PMID: 32481690
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms21113843